通过血清肿瘤标志物CA 19-9评估转移性胰腺癌的预后：化疗前水平还是化疗期间的动力学变化？

Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: pretreatment levels or kinetics during chemotherapy?

作者信息

Boeck Stefan, Schulz Christoph, Stieber Petra, Holdenrieder Stefan, Weckbach Sabine, Heinemann Volker

机构信息

Department of Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Germany.

出版信息

Onkologie. 2007 Feb;30(1-2):39-42. doi: 10.1159/000097764. Epub 2007 Jan 26.

DOI:10.1159/000097764

PMID:17264524

Abstract

BACKGROUND

The carbohydrate antigen 19-9 (CA 19-9) is currently the most widely used serum tumor marker in pancreatic cancer (PC). CA 19-9 pretreatment levels as well as CA 19-9 kinetics during systemic chemotherapy can provide prognostic information regarding survival of patients with metastatic PC.

CASE REPORTS

We report the clinical course of 2 patients with metastatic PC who underwent palliative chemotherapy with gemcitabine. Both patients showed a significant elevation of pretreatment CA 19-9 levels (7,505 and 150,000 U/ml, respectively), however, subsequently they experienced a highly significant reduction (>90%) of CA 19-9 kinetics under gemcitabine chemotherapy. A good disease control and a clinical benefit response were achieved in both patients. Time to tumor progression was 30 weeks and 28 weeks, overall survival 14 months and 11 months, respectively.

CONCLUSION

These data indicate that CA 19-9 kinetics under chemotherapy may possibly serve as a useful surrogate marker for time to tumor progression and survival in advanced PC.

摘要

背景

糖类抗原19-9（CA 19-9）是目前胰腺癌（PC）中使用最广泛的血清肿瘤标志物。全身化疗期间的CA 19-9预处理水平以及CA 19-9动力学可以为转移性PC患者的生存提供预后信息。

病例报告

我们报告了2例接受吉西他滨姑息化疗的转移性PC患者的临床病程。两名患者的预处理CA 19-9水平均显著升高（分别为7,505和150,000 U/ml），然而，随后在吉西他滨化疗下他们的CA 19-9动力学显著降低（>90%）。两名患者均实现了良好的疾病控制和临床获益反应。肿瘤进展时间分别为30周和28周，总生存期分别为14个月和11个月。